Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

About the Cover

Cover Figure


Confocal fluorescence microscopy image of a glioblastoma biopsy from a patient treated with the hypoxia-activated prodrug AQ4N. The activated cytotoxic agent AQ4 (red) is found in the nuclei (blue) of glioblastoma tumor cells (green) undergoing DNA fragmentation as shown by the reconstructed three-dimensional z-stack image. AQ4 was preferentially generated in hypoxic tumor tissues compared with normal tissues, which showed the first successful targeting of hypoxic tumors with a bioreductive cytotoxic agent in this phase I clinical study. For further details, please see Albertella and colleagues on page 1096 of this issue.

[Table of Contents]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.